<DOC>
	<DOCNO>NCT01487200</DOCNO>
	<brief_summary>The purpose study evaluate safety , pharmacokinetics pharmacodynamics FX006 patient osteoarthritis knee .</brief_summary>
	<brief_title>Pharmacokinetic Pharmacodynamic Study FX006 Patients With Osteoarthritis Knee</brief_title>
	<detailed_description>This study double-blind , randomize , parallel-group , active comparator design . Twenty-four patient knee osteoarthritis ( OA ) randomize treat single IA injection 10 , 40 , 60 mg FX006 40 mg commercially available triamcinolone acetonide . Each patient evaluate total 6 week follow single IA injection . Following screening , safety , PK pharmacodynamics evaluate one ( 1 ) 48-hour in-patient period ( Day -1 Day 2 ) , two ( 2 ) 24-hour in-patient period ( Day 14-15 Day 42-43 ) seven ( 7 ) out-patient visit ( Days 3 , 4 , 5 , 8 , 22 , 29 36 ) .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Main Willingness ability comply study procedure visit schedule ability follow verbal write instruction Male female &gt; =35 year age Diagnosis unilateral bilateral OA knee least 6 month prior Screening confirmation OA accord American College Rheumatology Criteria Classification Idiopathic OA Knee ( clinical radiological ) base Xray perform within 6 month prior Screening Screening period Body mass index ( BMI ) â‰¤ 40 kg/m2 Willingness abstain use protocolspecified restricted medication Main History Reiter 's syndrome , rheumatoid arthritis , psoriatic arthritis , ankylose spondylitis , arthritis associate inflammatory bowel disease , sarcoidosis amyloidosis History arthritides due crystal ( e.g. , gout , pseudogout ) History infection index joint Clinical sign symptom active knee infection crystal disease index knee Presence surgical hardware foreign body index knee Unstable joint ( torn anterior cruciate ligament ) IA corticosteroid ( investigational market ) joint within 3 month Screening IA hyaluronic acid ( investigational market ) index knee within 6 month Screening Oral , inhale intranasal corticosteroid ( investigational market ) within 1 month Screening Prior arthroscopic open surgery index knee within 12 month Screening Planned/anticipated surgery index knee study period History active malignancy , exception resect basal cell carcinoma , squamous cell carcinoma skin , resect cervical atypia carcinoma situ within 5 year Insulindependent diabetes History active Cushing 's syndrome Any clinically significant acute chronic medical condition ( e.g. , uncontrolled diabetes ) Skin breakdown knee injection would take place Women childbearing potential use effective contraception pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Osteoarthritis</keyword>
	<keyword>Knee</keyword>
	<keyword>Steroid</keyword>
	<keyword>intra-articular</keyword>
	<keyword>injection</keyword>
</DOC>